Photocure ASA

Photocure's partner Asieris Received China NMPA's Approval to Start a Global Phase III Clinical Trial for APL-1702 (Cevira)

Shanghai China, July 8, 2020 - Asieris Pharmaceuticals (Asieris), a China-based

biotech company with global aspirations to discover, develop and commercialize

innovative drugs for the treatment of genitourinary tumors and related diseases,

announced today it has received Clinical Trial Approval (CTA) from China's

National Medical Products Administration (NMPA) for the global, multi-centered

Phase III clinical trial of its photodynamic drug-device combination product,

APL-1702 (Cevira[®]), which is being developed for the non-surgical treatment of

high-grade cervical dysplasia (HSIL).

In addition to China, Asieris has concurrently initiated this global pivotal

trial in the United States, Germany, Romania, Hungary, Russia, Ukraine and other

European countries. Data from this trial will support the market approval

applications in China, the United States, the European Union, and other

countries.

Please read the full release here (http://www.asieris.cn/index.php/content/199).

About Photocure

Photocure: The Bladder Cancer Company delivers transformative solutions to

improve the lives of bladder cancer patients. Our unique technology, making

cancer cells glow bright pink, has led to better health outcomes for patients

worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo

Stock Exchange (OSE: PHO). For more information, please visit us at

AI Terminal